Value Creation, Valuation and Business Models in the Pharmaceutical Sector

Michael Blankenagel (), Jung Kyu Canci () and Philipp Mekler ()
Additional contact information
Michael Blankenagel: Lucerne University of Applied Sciences and Arts
Jung Kyu Canci: Lucerne University of Applied Sciences and Arts
Philipp Mekler: University of Basel

A chapter in Quantitative Models in Life Science Business, 2023, pp 3-16 from Springer

Abstract: Abstract The chapter describes value creation and valuation under structural uncertainty in the healthcare and pharma industries. These risks and uncertainties can significantly influence organizational performance, value creation and long-term sustainability. The discussion continues by comparing traditional valuation concepts used in finance with the requirements posed by the current situation of healthcare business. In particular, patent valuation is a critical business issue, and the value of pharma patents and licensing deals has risen markedly in recent years. Existing evaluation approaches do not consider a patent’s life cycle, an important and unique characteristic of pharma and biotech patents. For this reason, the inherent uncertainty in a patent’s value is modelled as a stochastic process.

Date: 2023
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:spbchp:978-3-031-11814-2_1

Ordering information: This item can be ordered from
http://www.springer.com/9783031118142

DOI: 10.1007/978-3-031-11814-2_1

Access Statistics for this chapter

More chapters in SpringerBriefs in Economics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().